Glaukos says Phase 4 trial shows iDose TR plus cataract surgery cuts mean diurnal IOP more than surgery alone

PUBT · 1d ago
Glaukos says Phase 4 trial shows iDose TR plus cataract surgery cuts mean diurnal IOP more than surgery alone
  • Glaukos reported positive topline results from a Phase 4 trial of iDose TR used during cataract surgery.
  • Results have been presented as topline data, not flagged for a future medical meeting in the announcement.
  • Patients receiving iDose TR with surgery showed better eye-pressure control than cataract surgery alone.
  • Safety profile through three months looked favorable, with no treatment-related serious corneal events reported.
  • Data support broader use of iDose TR in combined procedures, potentially expanding adoption beyond standalone glaucoma intervention.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261009307901) on October 09, 2026, and is solely responsible for the information contained therein.